Blood · 19 Nov 2026
NRAS knockdown reverses monocytic cell state and resensitizes resistant FLT3-AML cells to gilteritinib
Sunil K. Joshih-index 22, Hadi Maazi, Janét Pittsenbarger, Belinda B. Garana, Andy Kaempf, Ariane Huang, Marina A. Gritsenkoh-index 19, Chelsea Hutchinson, Karl K. Weitz, Rosalie K. Chu, Sara J. C. Gosline, Paul D. Piehowski, Ann-Kathrin Eisfeld, Martin Carrol, Alexander E. Perl, Karin D. Rodland, Bill H. Chang, Alexey Revenko, Jeffrey W. Tyner, Brian J. Druker, Elie Traerh-index 36
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- Crossref1
- OpenAlex1
- OpenCitations0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
Abstract Although the FLT3 inhibitor gilteritinib is initially effective in patients with FLT3-mutated acute myeloid leukemia (AML), patients invariably relapse within months of treatment. Gilteritinib resistance is commonly driven by the emergence of NRAS mutations and a shift toward a more monocytic cell state. We hypothesized that directly targeting and depleting NRAS protein would reverse these adaptive differentiation changes and restore therapeutic sensitivity. To test this, we used a mutation-agnostic antisense oligonucleotide (ASO) to selectively knock down NRAS expression across gilteritinib-resistant AML cell lines, in vivo cell line–derived xenografts, and primary patient samples. NRAS ASO successfully resensitized gilteritinib-resistant cells with multiple distinct NRAS mutations, displaying superior efficacy compared with downstream MEK inhibition. This therapeutic efficacy was independent of NRAS-mutant variant allele frequency, suggesting that wild-type NRAS may also contribute to resistance. Comprehensive multiomics profiling (transcriptomics, proteomics, and phosphoproteomics) revealed that NRAS knockdown consistently reversed the monocytic phenotype, shifting cells back toward a more primitive cell state. Monocytic differentiation and NRAS mutations are established drivers of resistance to diverse targeted regimens in AML, including FLT3, IDH, and BCL2 inhibitors. Therefore, we also tested venetoclax-resistant primary cells with NRAS mutations. Resistant cells were resensitized to venetoclax after NRAS knockdown, suggesting that NRAS knockdown may be more broadly applicable for overcoming monocytic cell state and drug resistance in AML.
What the data shows
- Crossref counts 1 citations, the most of the databases. The others count 0 to 1.
- Elie Traer has the highest h-index among the authors (36).
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (52)
What it cites, from open citation data, with Crossref's record of each.
Sign in to see 32 more references
A free account opens the rest of the citing papers and references on every paper’s page.